# A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old

> **NCT07722546** · PHASE2 · RECRUITING · sponsor: **Biogen** · enrollment: 60 (estimated)

## Conditions studied

- Graves' Disease

## Interventions

- **DRUG:** Felzartamab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07722546
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-30
- **Primary completion:** 2028-01-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07722546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07722546, "A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07722546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*